Graphene oxide nanoparticles and methods of use for stimulating immune responses

Patent metadata

Field	Value
Publication number	US-2024189415-A1
Application number	US-202218286191-A
Country	US
Kind code	A1
Filing date	Apr 8, 2022
Priority date	Apr 8, 2021
Publication date	Jun 13, 2024
Grant date	—

Abstract

Disclosed are functionalized graphene oxide nanoparticles and methods their use in inhibiting and treating microbial infection. The disclosure herein further provides for methods of making functionalized graphene oxide nanoparticles and said nanoparticles further incorporating microbial antigens for inducing antigen specific immune responses.

First claim

1 . A composition comprising i) a functionalized graphene oxide (GO) nanoparticle comprising polyethyleneimine (PEI) (GO-PEI, GP) and ii) a microbial antigen, vaccine, and/or pharmaceutical agent.

2 . The composition of claim 1 , wherein the functionalized graphene oxide (GO) nanoparticle comprising polyethyleneimine (PEI) (GO-PEI, GP) is PEGylated.

3 . The composition of claim 1 , wherein the functionalized graphene oxide (GO) nanoparticle forms a nanosheet.

4 . The composition of claim 1 , wherein the microbial antigen comprises a peptide, polypeptide, protein, inactivated virus, or heat killed virus.

5 . The composition of claim 1 , wherein the microbial antigen comprises a viral antigen from a virus selected from the group consisting of Herpes Simplex virus-1, Herpes Simplex virus-2, Varicella-Zoster virus, Epstein-Barr virus, Cytomegalovirus, Human Herpes virus-6, Variola virus, Vesicular stomatitis virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Rhinovirus, Coronavirus (including, but not limited to avian coronavirus (IBV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), HCoV-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, SARS-CoV, SARS-CoV-2 (including, but not limited to the B1.351 variant, B.1.1.7 variant, and P.1 variant), or MERS-CoV), Influenza virus A, Influenza virus B, Measles virus, Polyomavirus, Human Papilomavirus, Respiratory syncytial virus, Adenovirus, Coxsackie virus, Dengue virus, Mumps virus, Poliovirus, Rabies virus, Rous sarcoma virus, Reovirus, Yellow fever virus, Zika virus, Ebola virus, Marburg virus, Lassa fever virus, Eastern Equine Encephalitis virus, Japanese Encephalitis virus, St. Louis Encephalitis virus, Murray Valley fever virus, West Nile virus, Rift Valley fever virus, Rotavirus A, Rotavirus B, Rotavirus C, Sindbis virus, Simian Immunodeficiency virus, Human T-cell Leukemia virus type-1, Hantavirus, Rubella virus, Simian Immunodeficiency virus, Human Immunodeficiency virus type-1, and Human Immunodeficiency virus type-2.

6 . The composition of claim 5 , wherein the viral antigen comprises a peptide, polypeptide, or protein of an influenza virus hemagglutinin (HA) protein.

7 . (canceled)

8 . (canceled)

9 . The composition of claim 6 , wherein the HA protein comprises a trimeric HA.

10 . The composition of claim 5 , wherein the viral antigen comprises a peptide, polypeptide, or protein of a coronavirus spike protein or envelope protein; a peptide, polypeptide, or protein of a human immunodeficiency virus (HIV) glycoprotein (gp), envelope protein (Env), or gag protein; a peptide, polypeptide, or protein of a zika virus capsid protein, envelope protein, or premembrane/membrane protein; a peptide, polypeptide, or protein of a dengue virus capsid protein, envelope protein, or premembrane/membrane protein; a peptide, polypeptide, or protein of a Herpes Simplex (HSV)-1 or HSV-2 glycoprotein D or glycoprotein G: a peptide, polypeptide, or protein of a varicella zoster virus (VZV) glycoprotein E; a peptide, polypeptide, or protein of an Epstein-Barr virus (EBV) or Cytomegalovirus (CMV) glycoprotein; a peptide, polypeptide, or protein of a Respiratory synsyctial virus (RSV) G protein; a peptide, polypeptide, or protein of a measles virus hemagglutinin protein or fusion protein; a peptide, polypeptide, or protein of a rabies virus glycoprotein; a peptide, polypeptide, or protein of a rotavirus viral protein 4 or viral protein 7; a peptide, polypeptide, or protein of a hepatitis B virus surface antigen; or a peptide, polypeptide, or protein of a hepatitis C virus E1, E2, or E3 protein.

11 . (canceled)

12 . (canceled)

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . (canceled)

17 . (canceled)

18 . (canceled)

19 . (canceled)

20 . (canceled)

21 . (canceled)

22 . (canceled)

23 . The composition of claim 1 , wherein the microbial antigen comprises a bacterial antigen from a bacteria selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium bovis strain BCG, BCG substrains, Mycobacterium avium, Mycobacterium intracellular, Mycobacterium africanum, Mycobacterium kansasii, Mycobacterium marinum, Mycobacterium ulcerans, Mycobacterium avium subspecies paratuberculosis, Nocardia asteroides , other Nocardia species, Legionella pneumophila , other Legionella species, Bacillus anthracis, Acetinobacter baumanii, Salmonella typhi, Salmonella enterica , other Salmonella species, Shigella boydii, Shigella dysenteriae, Shigella sonnei, Shigella flexneri , other Shigella species, Yersinia pestis, Pasteurella haemolytica, Pasteurella multocida , other Pasteurella species, Actinobacillus pleuropneumoniae, Listeria monocytogenes, Listeria ivanovii, Brucella abortus , other Brucella species, Cowdria ruminantium, Borrelia burgdorferi, Bordetella avium, Bordetella pertussis, Bordetella bronchiseptica, Bordetella trematum, Bordetella hinzii, Bordetella pteri, Bordetella parapertussis, Bordetella ansorpii other Bordetella species, Burkholderia mallei, Burkholderia psuedomallei, Burkholderia cepacian, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydia psittaci, Coxiella burnetii, Rickettsial species, Ehrlichia species, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Vibrio cholerae, Campylobacter species, Neiserria meningitidis, Neiserria gonorrhea, Pseudomonas aeruginosa , other Pseudomonas species, Haemophilus influenzae, Haemophilus ducreyi , other Hemophilus species, Clostridium tetani , other Clostridium species, Yersinia enterolitica , and other Yersinia species.

24 . The composition of claim 1 , wherein the pharmaceutical agent comprises zanamivir, oseltamivir, peramivir, baloxavir, midazolam, lorazepam, flumazenil, dexmedetomidine, ketamine, fentanyl, hydromorphone, butorphanol, naloxone, insulin, fluticasone, ciclesonide, budesonide, dupilumab, mometasone, albuterol, reslizumab, zileuton, mepolizumab, omalizumab, and haloperidol.

25 . The composition of claim 1 , wherein the weight-to-weight ratio of GO-PEI particles to microbial antigen ranging from 10:1 to 1:10.

26 . The composition of claim 1 , further comprising an adjuvant.

27 . The composition of claim 26 , wherein the adjuvant comprises CpG oligonucleotide (CpG ODN).

28 . The composition of claim 26 , wherein the weight-to-weight ratio of GO-PEI particles to microbial antigen to adjuvant comprises 10:5:2.5 or 10:5:1.

29 . The composition of claim 1 , wherein the combination of a functionalized GO nanoparticle, microbial antigen with or without an adjuvant has a diameter of about 50 to about 300 nm.

30 . The composition of claim 1 , wherein the composition has a tunable zeta potential.

31 . A vaccine comprising the composition of claim 1 .

32 . A method of inhibiting a microbial infection, treating a microbial infection, inducing an immune response in a subject to a microbial antigen, vaccine, or pharmaceutical antigen, or delivering an antigen, vaccine, and/or pharmaceutical agent to a mucosal surface of a subject comprising administering to a subject at risk of being infected with a microbe or infected with a microbe, the vaccine of clai

Assignees

• Univ Georgia State Res Found

Inventors

• Wang Baozhong
• Dong Chunhong

Classifications

• C12N2760/16171

  Demonstrated in vivo effect · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title